Reframe Daily: New fluid may save more kidneys; smarter tumor picks and a fresh fix for blistering disease

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A new fluid kept donor kidneys healthier during machine perfusion; scientists mapped why some NF1-mutant brain tumors respond to MEK drugs; researchers identified the T cells that drive palmoplantar pustulosis blisters; a study showed osteoblasts burn nearby fat to power parathyroid-hormone bone growth; and blocking the BLT1 receptor on neutrophils stopped mucous membrane pemphigoid in mice.

Christin’s note: received a bunch of lovely questions yesterday! A few I answered immediately and the rest I will do so in video form. :)

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A better “preservation fluid” kept donor kidneys healthier during machine perfusion—so more kidneys could be usable for transplant.

Metabolite-enhanced normothermic machine perfusion improves kidney transplant viability

Market readiness: 🙂🙂🙂🙂 (NMP is already used clinically in some centers; this improved buffer could move into practice after targeted validation/QA rather than brand-new device approvals.) 

Good news: Scientists mapped why a tough brain tumor (NF1-mutant glioblastoma) responds differently to MEK drugs—pointing to smarter, more personal treatment picks.

Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma

Market readiness: 🙂🙂 (actionable biomarkers toward selecting among already-available MEK inhibitors, but still needs prospective clinical validation before changing care.) 

Good news: In a painful hand-and-foot skin disease (palmoplantar pustulosis), the main immune cells making the trouble-signal proteins (IL-17F, IL-26) were identified—clear drug targets.

Th17 cells with regulatory phenotype are the main IL-17F and IL-26 producers in palmoplantar pustulosis

Market readiness: 🙂🙂 (maps to existing cytokine-blocking strategies, but requires PPP-specific trials.) 

Good news: Bones don’t build themselves from thin air—this study shows they burn nearby fat to power hormone-driven bone formation, a clue that could boost osteoporosis therapy.

Mitochondrial β-oxidation of adipose-derived fatty acids by osteoblasts fuels parathyroid hormone–induced bone formation

Market readiness: 🙂🙂 (mechanism opens combo/diet/drug ideas, but not yet a clinical protocol.) 

Good news: Blocking a key “homing” receptor (BLT1) on neutrophils shut down disease in a model of mucous membrane pemphigoid (a blistering mouth/eye condition)—a new therapy angle.

The receptor BLT1 is essential on neutrophils in a mouse model of mucous membrane pemphigoid

Market readiness: 🙂 (strong preclinical signal; needs human safety/efficacy studies.) 

Thank you for taking the time to take care of yourself and your loved ones.